Orakl Oncology
Oncology drug discovery and clinical-response prediction for biopharma companies and research hospitals
Highlights
- Young companyFounded 2023
- New on EvolcAdded 2026-11-01
About Orakl Oncology
Orakl Oncology develops AI and biological-data products for cancer drug discovery and development. Its platform uses patient-derived tumor organoids, drug-response screening, genomic and other multimodal data, and clinical histories to identify therapeutic targets and predict patient responses.
Its O-Predict product supports clinical-trial endpoint prediction, biomarker identification, drug-combination analysis, and benefit–risk assessment. O-Target identifies potential therapeutic targets; the company serves biopharma partners and hospital and academic research networks.
Orakl Oncology is a spin-off from Gustave Roussy, founded in 2023 and headquartered in Villejuif, France. It announced an €11 million seed round and has a team of 10–19 employees.
Product: AI-enabled oncology drug-development services for clinical response prediction, biomarker analysis, drug combinations, and therapeutic-target discovery.
Jobs at Orakl Oncology
More biotech & pharma companies
Organotechnie
Manufactures peptones, protein hydrolysates and magnesium pidolate for pharmaceutical, biotechnology and industrial fermentation customersNew on EvolcOsivax
Develops universal vaccines for influenza and other infectious diseases using an oligoDOM nanoparticle platformNew on EvolcPanpharma
Develops, manufactures and distributes injectable medicines for healthcare establishments in more than 100 countriesNew on EvolcPhysiogenex
Preclinical drug testing and research services for pharmaceutical, biotechnologyNew on EvolcPK Med
Develops injectable biodegradable micro-implants for local drug delivery in rheumatology and hematologyNew on EvolcPoietis
Laser-assisted bioprinting systems for research laboratories and clinical tissue manufacturersNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- NuxtHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
- VueMedium confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Related technologyimplied by Nuxt
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.